Biofrontera Share Price (NASDAQ: BFRI)

$0.87

▲

0.01

(1.16%)

Live

Last updated on August 28, 2025 at 11:41 pm IST

$₹

Check the interactive Biofrontera Stock chart to analyse performance

Biofrontera stock performance

as on August 28, 2025 at 11:41 pm IST

Today's Low:$0.87
Today's High:$0.90
$0.87
0.0%
Downside
Day's Volatility :3.33%
Upside
3.33%
52 Weeks Low:$0.54
52 Weeks High:$2.22
$0.87
38.39%
Downside
52 Weeks Volatility :75.86%
Upside
60.81%

Biofrontera Stock Returns

Period	Biofrontera Inc	Index (Russel 2000)
3 Months	40.94%	0.0%
6 Months	-11.86%	0.0%
1 Year	-15.69%	0.0%
3 Years	-96.29%	-6.9%

Biofrontera Inc Key Stats

Check Biofrontera key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$0.86
Open	$0.88
Today's High	$0.9
Today's Low	$0.85
Market Capitalization	$9.6M
Today's Volume	$83.7K
52 Week High	$2.22
52 Week Low	$0.536
Revenue TTM	$39.2M
EBITDA	$-16.1M
Earnings Per Share (EPS)	$-1.82
Profit Margin	-42.34%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-531.54%

Stock Returns calculator for Biofrontera Stock including INR - Dollar returns

The Biofrontera stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Biofrontera investment value today

Current value as on today

₹89,654

Returns

₹10,346

(-10.35%)

Returns from Biofrontera Stock

₹14,706 (-14.71%)

Dollar Returns*

₹4,360 (+4.36%)

Indian investors sentiment towards Biofrontera Stock

50%

Period: Jul 28, 2025 to Aug 27, 2025. Change in 30 Days versus previous period

Search interest for Biofrontera Stock from India on INDmoney has increased by 50% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Biofrontera Inc

Name
Holdings %
Name
Holdings %
AIGH Capital Management, LLC
9.61%
Rosalind Advisors, Inc.
6.36%
Geode Capital Management, LLC
0.40%
Citadel Advisors Llc
0.28%
Virtu Financial LLC
0.18%
XTX Topco Ltd
0.11%

Analyst Recommendation on Biofrontera Stock

Rating

Trend

Buy

87%Buy

12%Hold

0%Sell

Based on 8 Wall street analysts offering stock ratings for Biofrontera(by analysts ranked 0 to 5 stars)

Biofrontera Share Price Target

What analysts predicted

Upside of 647.13%

Target:

$6.50

Current:

$0.87

Biofrontera share price target is $6.50, a slight Upside of 647.13% compared to current price of $0.87 as per analysts' prediction.

Biofrontera Stock Insights

Price Movement
In the last 3 years, BFRI stock has moved down by -96.5%
Increasing Revenue
Revenue is up for the last 2 quarters, 8.58M → 9.03M (in $), with an average increase of 4.9% per quarter
Decreasing Net Profit
Netprofit is down for the last 3 quarters, -1.39M → -5.32M (in $), with an average decrease of 113.9% per quarter
BFRI vs NBIX (1 yr)
In the last 1 year, Neurocrine Biosciences Inc. has given 11.6% return, outperforming this stock by 27.3%
BFRI vs HLN (3 yr)
In the last 3 years, Haleon Plc Spon Ads has given 31.7% return, outperforming this stock by 128.2%
Price to Sales
ForBFRI every $1 of sales, investors are willing to pay $0.2, whereas for Neurocrine Biosciences Inc., the investors are paying $5.5 for every $1 of sales.

Biofrontera Inc Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$26.2M	-
Net Income	$-11.0M	-
Net Profit Margin	-41.95%	-

	FY20	Y/Y Change
Revenue	$18.8M	↓ 28.01%
Net Income	$-11.0M	↑ 0.05%
Net Profit Margin	-58.29%	↓ 16.34%

	FY21	Y/Y Change
Revenue	$24.1M	↑ 27.86%
Net Income	$-37.7M	↑ 243.25%
Net Profit Margin	-156.49%	↓ 98.2%

	FY22	Y/Y Change
Revenue	$28.7M	↑ 18.98%
Net Income	$-640.0K	↓ 98.3%
Net Profit Margin	-2.23%	↑ 154.26%

	FY23	Y/Y Change
Revenue	$34.1M	↑ 18.82%
Net Income	$-20.1M	↑ 3045.47%
Net Profit Margin	-59.09%	↓ 56.86%

	FY24	Y/Y Change
Revenue	$37.3M	↑ 9.49%
Net Income	$-17.8M	↓ 11.78%
Net Profit Margin	-47.61%	↑ 11.48%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$7.9M	↓ 25.43%
Net Income	$-10.4M	↓ 396.0%
Net Profit Margin	-132.1%	↓ 165.38%

	Q2 FY24	Q/Q Change
Revenue	$7.8M	↓ 0.78%
Net Income	$-257.0K	↓ 97.54%
Net Profit Margin	-3.28%	↑ 128.82%

	Q3 FY24	Q/Q Change
Revenue	$9.0M	↑ 14.96%
Net Income	$-5.7M	↑ 2105.84%
Net Profit Margin	-62.91%	↓ 59.63%

	Q4 FY24	Q/Q Change
Revenue	$12.6M	↑ 39.27%
Net Income	$-1.4M	↓ 75.37%
Net Profit Margin	-11.12%	↑ 51.79%

	Q1 FY25	Q/Q Change
Revenue	$8.6M	↓ 31.58%
Net Income	$-4.2M	↑ 201.07%
Net Profit Margin	-48.94%	↓ 37.82%

	Q2 FY25	Q/Q Change
Revenue	$9.0M	↑ 5.15%
Net Income	$-5.3M	↑ 26.67%
Net Profit Margin	-58.96%	↓ 10.02%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$13.8M	-

	FY20	Y/Y Change
Profit	$9.8M	↓ 28.97%

	FY21	Y/Y Change
Profit	$11.4M	↑ 16.1%

	FY22	Y/Y Change
Profit	$13.5M	↑ 18.76%

	FY23	Y/Y Change
Profit	$16.6M	↑ 23.26%

	FY24	Y/Y Change
Profit	$18.7M	↑ 12.44%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$4.0M	↓ 24.35%

	Q2 FY24	Q/Q Change
Profit	$3.5M	↓ 11.58%

	Q3 FY24	Q/Q Change
Profit	$4.1M	↑ 18.24%

	Q4 FY24	Q/Q Change
Profit	$7.9M	↑ 90.11%

	Q1 FY25	Q/Q Change
Profit	$5.5M	↓ 29.87%

	Q2 FY25	Q/Q Change
Profit	$6.7M	↑ 20.62%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-37.7M	-
Investing Cash Flow	$25.4M	-
Financing Cash Flow	$16.4M	-

	FY20	Y/Y Change
Operating Cash Flow	$-12.4M	↓ 67.17%
Investing Cash Flow	$-11.0K	↓ 100.04%
Financing Cash Flow	$13.2M	↓ 19.55%

	FY21	Y/Y Change
Operating Cash Flow	$-26.7M	↑ 115.98%
Investing Cash Flow	$-11.0K	↑ 0.0%
Financing Cash Flow	$43.2M	↑ 227.35%

	FY22	Y/Y Change
Operating Cash Flow	$-16.2M	↓ 39.36%
Investing Cash Flow	$-5.2M	↑ 46772.73%
Financing Cash Flow	$14.0M	↓ 67.54%

	FY23	Y/Y Change
Operating Cash Flow	$-24.9M	↑ 53.68%
Investing Cash Flow	$619.0K	↓ 112.01%
Financing Cash Flow	$8.4M	↓ 40.01%

	FY24	Y/Y Change
Operating Cash Flow	$-10.3M	↓ 58.75%
Investing Cash Flow	$-3.0K	↓ 100.48%
Financing Cash Flow	$14.8M	↑ 76.38%

Q2 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-4.7M	↑ 41.95%
Investing Cash Flow	$-2.0K	-
Financing Cash Flow	$5.3M	↓ 8.88%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-1.0M	↓ 15.81%
Investing Cash Flow	$-1000.0	-
Financing Cash Flow	$4.1M	↓ 1459.06%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-4.1M	↑ 304.82%
Investing Cash Flow	$-3.0K	↑ 200.0%
Financing Cash Flow	$0.0	↓ 100.0%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$-3.0M	↓ 26.04%
Investing Cash Flow	$-1000.0	↓ 66.67%
Financing Cash Flow	$8.5M	-

Biofrontera Technicals Summary

Sell

Neutral

Buy

Biofrontera is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Biofrontera Inc Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Biofrontera Inc	-18.1%	-11.86%	-15.69%	-96.29%	-99.02%
Haleon Plc Spon Ads	-1.02%	-0.82%	-2.8%	59.97%	31.04%
United Therapeutics Corporation	2.62%	-5.65%	-15.14%	40.39%	71.72%
Zoetis Inc.	2.89%	-5.82%	-15.06%	-1.58%	-2.95%
Neurocrine Biosciences Inc.	2.94%	17.55%	11.61%	31.15%	18.65%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Biofrontera Inc	0.89	NA	NA	-1.34	-5.32	-0.49	NA	-0.46
Haleon Plc Spon Ads	21.4	21.4	3.13	0.49	0.09	0.05	0.01	1.77
United Therapeutics Corporation	11.91	11.91	1.43	26.59	0.19	0.13	NA	158.65
Zoetis Inc.	26.69	26.69	2.51	6.33	0.53	0.15	0.01	11.21
Neurocrine Biosciences Inc.	40.49	40.49	0.27	6.74	0.13	0.09	NA	27.22

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Biofrontera Inc	Buy	$9.6M	-99.02%	0.89	-42.34%
Haleon Plc Spon Ads	Buy	$43.9B	31.04%	21.4	13.81%
United Therapeutics Corporation	Buy	$13.8B	71.72%	11.91	40.36%
Zoetis Inc.	Buy	$68.6B	-2.95%	26.69	27.83%
Neurocrine Biosciences Inc.	Buy	$13.6B	18.65%	40.49	13.88%

About Biofrontera Inc

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a common skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Organization	Biofrontera
Employees	92
CEO	Dr. Hermann Luebbert Ph.D.
Industry	Miscellaneous

Key Management of Biofrontera Inc

Name	Title
Dr. Hermann Luebbert Ph.D.	CEO, President & Chairman
Mr. Eugene Frederick Leffler III	Chief Financial Officer
Ms. Erica F. Gates CPA, M.B.A.	Senior Director of Finance & Principal Accounting Officer
Mr. Jon Lyons M.B.A., Ph.D.	Vice President of Scientific & Medical Affairs
Mr. Daniel Hakansson J.D.	General Counsel & Head of Compliance

Important FAQs about investing in BFRI Stock from India :

What is Biofrontera share price today?

Biofrontera share price today is $0.87 as on August 28, 2025 at 11:41 pm IST. Biofrontera share today touched a day high of $0.90 and a low of $0.87.

What is the 52 week high and 52 week low for Biofrontera share?

Biofrontera share touched a 52 week high of $2.22 and a 52 week low of $0.54. Biofrontera stock price today i.e. August 28, 2025 at 11:41 pm IST is trending at $0.87, lower by 60.81% versus the 52 week high.

How to invest in Biofrontera Stock (BFRI) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Biofrontera on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Biofrontera Shares that will get you 1.7241 shares as per Biofrontera share price of $0.87 per share as on August 28, 2025 at 11:41 pm IST.

What is the minimum amount required to buy Biofrontera Stock (BFRI) from India?

Indian investors can start investing in Biofrontera (BFRI) shares with as little as ₹87.587 or $1 (as of August 28, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹875.87 in Biofrontera stock (as per the Rupee-Dollar exchange rate as on August 28, 2025). Based on Biofrontera share’s latest price of $0.87 as on August 28, 2025 at 11:41 pm IST, you will get 11.4943 shares of Biofrontera. Learn more about fractional shares .

What are the returns that Biofrontera has given to Indian investors in the last 5 years?

Biofrontera stock has given -99.02% share price returns and 18.52% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?